Email this article Bendamustin v terapii nekhodzhkinskikh limfom
- Authors: Semenova AA1
-
Affiliations:
- ФГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
- Issue: Vol 14, No 2 (2012)
- Pages: 10-12
- Section: Articles
- URL: https://ogarev-online.ru/1815-1434/article/view/29479
- ID: 29479
Cite item
Abstract
About the authors
A A Semenova
ФГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, МоскваФГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
References
- United States Food and Drug Administration. Approval letter NDA 22-249. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/ 022249s000ltr.pdf
- United States Food and Drug Administration. Approval letter NDA 22-303. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/ 022303s000ltr.pdf
- Anger G, Hesse P, Baufield H. Treatment of multiple myeloma with a new cytostatic agent: g-1-methyl-5-bis-(b-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride. Dtsch Med Wochenschr 1969; 94: 2495-500.
- Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-17.
Supplementary files
